CITIUS PHARMACEUTICALS Aktie

>CITIUS PHARMA Performance

1 Woche: 0%

1 Monat: 0%

3 Monate: 0%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: 0%

>CITIUS PHARMACEUTICALS Aktie

Name:

CITIUS PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US17322U3068 / A40MD0

Symbol/ Ticker:

47N0 (Frankfurt) / CTXR (NASDAQ)

Kürzel:

FRA:47N0, ETR:47N0, 47N0:GR, NASDAQ:CTXR

Index:

Webseite:

https://www.citiuspharma...

Profil:

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company specializing in the development and commercialization of first-in-class critical care products. The company focuses on innovative therapies primarily in anti-infectives, oncology,..
>Volltext..

Marktkapitalisierung:

16.56 Mio. EUR

Unternehmenswert:

23.16 Mio. EUR

Umsatz:

3.42 Mio. EUR

EBITDA:

-31.87 Mio. EUR

Nettogewinn:

-31.09 Mio. EUR

Gewinn je Aktie:

-2.51 EUR

Schulden:

1.59 Mio. EUR

Liquide Mittel:

6.69 Mio. EUR

Operativer Cashflow:

-30.18 Mio. EUR

Bargeldquote:

0.2

Umsatzwachstum:

Gewinnwachstum:

9.55%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CITIUS PHARMACEUTICALS, CITIUS PHARMA, CITIUS PHARMACEUTICAL

Letzte Datenerhebung:

04.04.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 22.38 Mio. St.

Frei handelbar: 97.63%

Leerverk. Aktien: 18.08%

Rückkaufquote: -278.23%

Mitarbeiter: 23

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 602.41%

Bewertung:

KGV: -

KGV lG: 0.51

KUV: 4.59

KBV: 0.24

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 61.41%

Gewinnmarge: -909.87%

Operative Marge: -950.92%

Managementeffizenz:

Gesamtkaprendite: -27.49%

Eigenkaprendite: -49.37%

>Peer Group

Gesundheit, Medizin für Bakterielle- & Pilzinfektionen/ Antibiotika, Onkologie/ Krebs- Behandlung, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>CITIUS PHARMA Chart & Kurs - NASDAQ

>CITIUS PHARMA News

13.02.26 - 14:03	Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ (PR Newswire)
	Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical......

24.12.25 - 08:54	Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here′s Why (Benzinga)
	Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update. read more...

23.12.25 - 22:39	Citius Pharmaceuticals GAAP EPS of -$3.38 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.12.25 - 22:39	Citius Pharmaceuticals GAAP EPS of -$3.38 misses by $0.25 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.12.25 - 22:33	Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update (PR Newswire)
	Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025 CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and......

10.12.25 - 22:33	Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
	CRANFORD, N.J., Dec. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the closing of its previously announced registered......

01.12.25 - 18:03	Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) (PR Newswire)
	LYMPHIR now available nationwide CRANFORD, N.J., Dec. 1, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the commercial launch of LYMPHIR™......

24.11.25 - 05:45	Butterfly Network, Citius Pharma Drive Biotech Momentum In After-Hours Trading (RTTNews)
	Biotech and healthcare stocks saw notable activity in Friday's after-hours trading session, with several names posting sharp moves on the back of corporate updates and investor anticipation. Here are the highlights from November 21, 2025....

21.10.25 - 22:33	Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire)
	CRANFORD, N.J., Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced the closing of its......

20.10.25 - 16:01	Citius Oncology Inks Distribution Services Agreement With McKesson For LYMPHIR (AFX)
	WASHINGTON (dpa-AFX) - Citius Oncology, Inc. (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (CTXR), announced Monday it has entered into a distribution services agreement ......

20.10.25 - 14:39	Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch (PR Newswire)
	McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIR CRANFORD, N.J., Oct. 20, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma")......

17.10.25 - 23:03	Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences (PR Newswire)
	LD Micro Main Event XIX, October 19-21, 2025 2025 Maxim Growth Summit, October 22-23, 2025 The Think Equity Conference, October 30, 2025 CRANFORD, N.J., Oct. 17, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and Citius Oncology, Inc. (Nasdaq: CTOR) today announced that......

10.09.25 - 22:33	Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
	CRANFORD, N.J., Sept. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class......

12.08.25 - 22:48	Citius Pharmaceuticals GAAP EPS of -$0.08 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.08.25 - 22:33	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
	$12.5 million in gross financings raised during the quarter, with an additional $9 million raised by Citius Oncology in July 2025, to facilitate LYMPHIR pre-launch initiatives and drive successful market introduction CRANFORD, N.J., Aug. 12, 2025 /PRNewswire/ -- Citius Pharmaceuticals,......

12.08.25 - 22:33	Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
	LYMPHIR commercial availability planned for the fourth quarter of 2025 $12.5 million in gross financings raised during the quarter by Citius Pharmaceuticals, with an additional $9 million raised by Citius Oncology in July 2025, to facilitate LYMPHIR pre-launch initiatives and drive......

17.07.25 - 22:33	Citius Oncology Announces Closing of $9.0 Million Public Offering (PR Newswire)
	CRANFORD, N.J., July 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the closing of its "reasonable best-efforts" public offering of 6,818,182......

16.07.25 - 15:18	Citius Oncology Announces Pricing of $9.0 Million Public Offering (PR Newswire)
	CRANFORD, N.J., July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the pricing of its "reasonable best-efforts" public offering of 6,818,182......

08.07.25 - 14:54	Citius Pharmaceuticals regains Nasdaq compliance (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.07.25 - 14:36	Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
	CRANFORD, N.J. , July 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) today announced that it has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") indicating that for 10 consecutive trading days, from June 20,......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Frauen bewundern einen Mann wegen seiner Stärke, aber sie lieben ihn wegen seiner Schwächen. - Beatrice Brown

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram